PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor. This drug is presently in Phase III clinical trials, targeting patients who are experiencing severe, uncontrolled, or life-threatening bleeding events, or those requiring immediate surgical or invasive interventions.